MT477 family of therapeutic compounds
Treatment for Non-small Cell Lung Cancer
Updated: August 14, 2007
 

The following is a brief description of MT477 and is updated periodically to reflect the status of pre-clinical studies and licensing activity. 

Product Family

The MT477 family of therapeutic compounds was screened from tens of thousand of designed candidates with an optimal activity profile against non-small cell lung cancer, using Medisyn’s Forward Engineering™ in silico techniques.  MT477 predictions for activity and specificity have been validated in vitro with the National Cancer Institute (NCI) 3-cell and 60-cell line testing. In addition to identifying active chemical analogs, Medisyn has designed “property analogs” as backup lead candidates – these are chemically diverse structures possessing the same therapeutic properties as MT477. Drug-like MT477 and its analogs show remarkable promise and potential as candidates for pre-clinical and clinical evaluation. 

At-a-glance

• Recent in vivo studies show

  • Cisplatin equivalency

  • Well tolerated

  • No weight loss

  • No blood or organ effects